Efficacy and safety of Immune Checkpoint Inhibitors in Lung Cancer Patients with Combined Pulmonary Fibrosis and Emphysema - Vienna 2024

Deep in clinical dilemmas of non-idiopathic interstitial lung diseases

Chair(s): Paolo Spagnolo, Gautam George

Session type: Poster session

Efficacy and safety of Immune Checkpoint Inhibitors in Lung Cancer Patients with Combined Pulmonary Fibrosis and Emphysema

Haruka Chin

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Pneumotoxicity ASSociated With Rheumatological Drugs (PASSWRD) A modified Delphi

Nazia Chaudhuri

Poster

Abstract

Impact of different diagnostic criteria in hypersensitivity pneumonitis: a centers experience

Rita Vasconcelos Rodrigues Pereira

Poster

Abstract

Comparing CPET and 6MWT for Assessing Exercise Capacity in Systemic Sclerosis Patients with Pulmonary Involvement

?ukasz Minarowski

Poster

Abstract

Comparative risk of interstitial lung disease (ILD) among Trastuzumab Deruxtecan (T-DXd) and other anti-breast cancer drugs: a VigiBase pharmacovigilance study approach.

Lana Elu

Poster

Abstract

Home environmental fungal exposure in patients with Hypersensitivity Pneumonitis

David Jorge Ara?jo Barros Coelho

Poster

Abstract

Understanding the Effects of COVID-19 on Respiratory Function:Insights from Interstitial Lung Disease

Imen Talbi

Poster

Abstract

Prevalent comorbidity in patients with hypersensitivity pneumonitis: a UK primary care population study

Daryl Cheng

Poster

Abstract

Systemic Sclerosis: Can Breathomics Monitor Interstitial Lung Disease?

Thibault Massenet

Poster

Abstract

Hypersensitivity pneumonitis- single center data from Hungary

Sarah Brack

Poster

Abstract

A rapid diagnostic circuit for ILD improves the patient journey

Guadalupe Bermudo Peloche

Poster

Abstract

Approaches in diagnosis, follow-up and treatment of patients with progressive pulmonary fibrosis: a questionnaire study

Nilg?n Yilmaz Demirci

Poster

Abstract

Drug-induced interstitial lung disease: a nationwide observational study over 37 years using the French pharmacovigilance database

Sophie Yavordios

Poster

Abstract

Longitudinal Outcomes and Risk Factors Associated with COVID-19 Pulmonary Fibrosis : A Comprehensive Analysis.

Won Jin Yang

Poster

Abstract

Hypersensitivity Pneumonitis with and without Autoimmune Features: a comparative analysis at diagnosis

Joana Catarina Neto Louren

Poster

Abstract

Efficacy and safety of Immune Checkpoint Inhibitors in Lung Cancer Patients with Combined Pulmonary Fibrosis and Emphysema

Haruka Chin

Poster

Abstract

Integrating forced vital capacity and fibrotic radiological score in interstitial lung disease (FIBRO-ILD)

Chen Yong Tan

Poster

Abstract

Long-term Experience in Fibrotic Hypersensitivity Pneumonitis: A Comprehensive Study of Progressive Pulmonary Fibrosis at a Tertiary Center

Maria Florencia Pilia

Poster

Abstract

Recurrence risk factors for organizing pneumonia: a single-center retrospective cohort study

Yuki Sato

Poster

Abstract

Prevalence and impact of SARS-CoV-2 infection in interstitial lung disease patients: an exploratory experience in two tertiary centers in South Italy

Ludovica Capitelli

Poster

Abstract

RCT Abstract - Inhaled molgramostim improves pulmonary gas exchange and respiratory health-related quality of life (HRQoL) in patients with autoimmune pulmonary alveolar proteinosis (aPAP): Results from IMPALA-2

Bruce Trapnell

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}